Takeda Pharmaceutical Co Ltd v. Sun Pharmaceutical Industries Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Takeda Pharmaceutical Company Limited (Japan)
  • Defendant: Sun Pharmaceutical Industries Ltd. (India)
  • Plaintiff's Counsel: Saul Ewing LLP
• Case Identification: 2:26-cv-02051, D.N.J., 02/26/2026
• Venue Allegations: Plaintiff alleges venue is proper because Defendant conducts business in the United States, including the District of New Jersey, and that the district is a likely destination for the accused generic drug product. The complaint further alleges that Defendant has previously consented to personal jurisdiction in this district in numerous prior patent cases.
• Core Dispute: Plaintiff alleges that Defendant's Abbreviated New Drug Application to market a generic version of LIVTENCITY® (maribavir) infringes six U.S. patents related to the drug's composition, synthesis, and methods of use.
• Technical Context: The technology relates to maribavir, a cytomegalovirus (CMV) pUL97 kinase inhibitor used to treat post-transplant CMV infections that are refractory to other antiviral treatments.
• Key Procedural History: This action was initiated under the Hatch-Waxman Act following Defendant's submission of an Abbreviated New Drug Application (ANDA) with a Paragraph IV Certification, asserting that its generic product would not infringe Plaintiff's patents or that the patents are invalid. The complaint also notes related litigation against other generic drug manufacturers concerning the same patents.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,684,632 - "Maribavir Isomers, Compositions, Methods of Making and Methods of Using"

The Invention Explained

• Problem Addressed: The patent's background section describes the unexpected discovery that the antiviral drug maribavir may isomerize (i.e., convert into different molecular structures) when in the body, which can dilute the concentration of the effective drug form and reduce its therapeutic efficacy '632 Patent, col. 2:5-18 This phenomenon was identified as a potential reason for inconsistent clinical trial results, where a study allowing patients to take the drug with food failed after a prior study requiring fasted administration had succeeded '632 Patent, col. 2:19-56
• The Patented Solution: The invention provides methods to enhance maribavir's therapeutic effect by controlling administration conditions to mitigate in vivo isomerization. The patent claims methods of treating herpes viral infections, such as cytomegalovirus (CMV), in transplant recipients by orally administering a specific dose of maribavir (400 mg twice a day) under particular conditions, including "fasted conditions" '632 Patent, col. 8:1-5 '632 Patent, claim 3
• Technical Importance: The invention provides a specific dosing regimen intended to ensure consistent bioavailability and efficacy of maribavir by controlling a variable (food intake) that could otherwise lead to chemical changes that reduce the drug's potency.

Key Claims at a Glance

• The complaint alleges infringement of one or more claims of the '632 patent Compl. ¶34 The patent contains three independent claims: 1, 6, and 11.
• Independent Claim 1: A method for treatment of a herpes viral infection comprising:
  • Orally administering to a stem cell transplant recipient
  • the compound 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole, or an isomer thereof
  • in an amount of 400 mg twice a day.
• Independent Claim 6: A method for treatment of a herpes viral infection comprising:
  • Orally administering to a kidney transplant recipient
  • the compound 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole, or an isomer thereof
  • in an amount of 400 mg twice a day.
• Independent Claim 11: A method for treatment of a herpes viral infection comprising:
  • Orally administering to a liver transplant recipient
  • the compound 5,6-dichloro-2-(isopropylamino)-1-(β-L-ribofuranosyl)-1H-benzimidazole, or an isomer thereof
  • in an amount of 400 mg twice a day.

U.S. Patent No. 12,213,989 - "Use of Maribavir in Treatment Regimens"

The Invention Explained

• Problem Addressed: The patent's background describes that maribavir is metabolized in the body by the CYP3A4 enzyme. When co-administered with other drugs that are "CYP3A4 inducers" (such as certain anticonvulsants), the metabolism of maribavir can be accelerated, leading to decreased drug exposure and potentially reduced antiviral efficacy '989 Patent, col. 1:13-16 '989 Patent, col. 2:7-9
• The Patented Solution: The invention provides a method for managing this specific drug-drug interaction. The solution involves administering an increased dose of maribavir (1200 mg orally twice daily) to transplant recipients who are also receiving certain anticonvulsants (phenytoin or phenobarbital) that induce the CYP3A4 enzyme '989 Patent, abstract '989 Patent, claim 1 This dose adjustment is designed to counteract the increased metabolism and maintain therapeutic concentrations of maribavir.
• Technical Importance: The invention provides a specific dosing protocol to maintain the efficacy of maribavir in transplant patients, a population often requiring complex, multi-drug regimens, thereby addressing a known metabolic pathway for drug-drug interactions.

Key Claims at a Glance

• The complaint alleges infringement of one or more claims of the '989 patent Compl. ¶43 The patent contains one independent claim.
• Independent Claim 1: A method of treating a cytomegalovirus (CMV) infection in a patient comprising:
  • Administering maribavir in an amount of 1200 mg orally twice daily
  • wherein the patient is a transplant recipient concomitantly exposed to or receiving an anticonvulsant selected from phenytoin or phenobarbital.

U.S. Patent No. 12,295,940 - "Viral Inhibitors, the Synthesis Thereof, and Intermediates Thereto"

• Technology Synopsis: The patent discloses improved, scalable methods for synthesizing maribavir that can increase the overall yield and purity of the final drug product '940 Patent, abstract '940 Patent, col. 1:18-21 It claims maribavir compositions characterized by very low levels of specific, named process-related impurities '940 Patent, claim 1
• Asserted Claims: The complaint is general Compl. ¶52 Independent claims are 1 and 37.
• Accused Features: The complaint alleges that Sun's ANDA product is a composition that infringes the '940 patent's claims Compl. ¶54

U.S. Patent No. 12,433,907 - "Use of Maribavir in Treatment Regimens"

• Technology Synopsis: This patent, from the same family as the '989 patent, addresses drug-drug interactions between maribavir and CYP3A4 inducers. It claims a method of treating CMV in a transplant recipient by administering a 1200 mg twice-daily dose of maribavir when the patient is also receiving an anticonvulsant (phenytoin or phenobarbital) and further requires monitoring immunosuppressant drug levels '907 Patent, abstract '907 Patent, claim 1 '907 Patent, claim 17
• Asserted Claims: The complaint is general Compl. ¶61 Independent claim is 1.
• Accused Features: The complaint alleges that use of Sun's ANDA product as instructed by its label will infringe the claimed method, and that Sun will induce such infringement Compl. ¶64

U.S. Patent No. 12,447,169 - "Maribavir Isomers, Compositions, Methods of Making and Methods of Using"

• Technology Synopsis: This patent, from the same family as the '632 patent, addresses the in vivo isomerization of maribavir. It claims a method of treating CMV by administering 400 mg of maribavir twice a day, wherein the compound is specifically administered "with food" '169 Patent, abstract '169 Patent, claim 2 This provides an alternative dosing regimen to the "fasted condition" claims of the related '632 patent.
• Asserted Claims: The complaint is general Compl. ¶70 Independent claim is 1.
• Accused Features: The complaint alleges that use of Sun's ANDA product as instructed by its label will infringe the claimed method, and that Sun will induce such infringement Compl. ¶73

U.S. Patent No. 12,447,170 - "Use of Maribavir in Treatment Regimens"

• Technology Synopsis: This patent, also from the same family as the '989 patent, addresses drug-drug interactions. It claims methods of treating CMV in a transplant recipient who is receiving an anticonvulsant by administering an increased dose of maribavir (e.g., 800 mg or 1200 mg twice daily) "selected to counteract the effect of the anticonvulsant" and also monitoring immunosuppressant levels ('170 Patent, abstract; '170 Patent, claims 1, 17).
• Asserted Claims: The complaint is general Compl. ¶79 Independent claims are 1 and 17.
• Accused Features: The complaint alleges that use of Sun's ANDA product as instructed by its label will infringe the claimed method, and that Sun will induce such infringement Compl. ¶82

III. The Accused Instrumentality

• Product Identification: The accused instrumentality is Defendant Sun's generic maribavir tablets, 200 mg, for which it seeks FDA approval via ANDA No. 219690 ("Sun's ANDA Product") Compl. ¶28
• Functionality and Market Context: Sun's ANDA Product is intended to be a generic version of Plaintiff's LIVTENCITY® drug product Compl. ¶32 LIVTENCITY® is indicated for the treatment of post-transplant cytomegalovirus (CMV) infection that is refractory to treatment with other antiviral drugs Compl. ¶10 The complaint alleges that upon approval, Sun will manufacture, use, sell, and import its generic product in the United States, directly competing with LIVTENCITY® Compl. ¶29 The complaint asserts that the FDA-approved labeling for Sun's product will instruct users to administer it in a manner that infringes the asserted method patents Compl. ¶13

IV. Analysis of Infringement Allegations

The complaint does not provide a detailed, element-by-element infringement analysis or claim chart for the asserted patents. The infringement allegations are premised on Defendant's submission of ANDA No. 219690 seeking approval to market a generic version of LIVTENCITY® prior to the expiration of the patents-in-suit, which constitutes a statutory act of infringement under 35 U.S.C. § 271(e)(2)(A) Compl. ¶34 Compl. ¶43 Compl. ¶52 Compl. ¶61 Compl. ¶70 Compl. ¶79

For the asserted method patents, the complaint's theory of infringement relies on inducement, alleging that the FDA-approved labeling for Sun's ANDA Product will instruct and encourage physicians and patients to administer the drug in a manner that directly infringes the claimed methods Compl. ¶13 Compl. ¶37 Compl. ¶46 Compl. ¶64 Compl. ¶73 Compl. ¶82 For the asserted composition patent ('940 patent), the complaint alleges that the ANDA product itself will have the claimed composition Compl. ¶54

No probative visual evidence provided in complaint.

• Identified Points of Contention:
  • Label-Based Inducement: For the method patents ('632, '989, '907, '169, and '170), a central question will be whether the proposed label for Sun's generic product will instruct or encourage administration in a way that meets all limitations of the asserted claims. This may include instructions regarding administration with or without food, or specific dose adjustments when co-administered with certain anticonvulsants.
  • Factual Composition: For the '940 patent, the dispute will likely be factual, centering on whether Sun's ANDA product, as manufactured, actually contains the claimed composition, specifically with respect to the low levels of impurities recited in the claims. This will likely require chemical analysis of Sun's product samples during discovery.
  • Claim Scope: The relationship between patents claiming administration "with food" '169 Patent and "under fasted conditions" '632 Patent suggests that the interpretation of these terms will be a key issue for determining the scope of infringement or non-infringement.

V. Key Claim Terms for Construction

The complaint does not identify any specific claim terms for construction. However, based on the patents-in-suit, the following terms may be central to the dispute.

• The Term: "fasted condition" ('632 Patent, e.g., claim 3)

• Context and Importance: The '632 patent claims administration under "fasted conditions," while the related '169 patent claims administration "with food." The precise definition of "fasted condition" will establish the boundary between the two patents and will be critical for determining whether a particular administration infringes one patent, the other, or neither. Practitioners may focus on this term to define the scope of the claimed method.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The specification provides a general definition: "the condition of not having consumed food during the period between from at least about 3 to 12 hours prior to the administration...to at least about 1 to 3 hours after the administration" '632 Patent, col. 5:56-62 The use of "in general" and "about" may support a flexible interpretation.
  • Evidence for a Narrower Interpretation: The same definition provides specific time windows (e.g., "3 to 12 hours prior"). A party could argue these create firm temporal boundaries. The patent's background also heavily references the protocol of the "200 Study," which could be used to argue that "fasted condition" should be limited to the specific protocol of that clinical trial '632 Patent, col. 2:40-48

• The Term: "concomitantly exposed to or receiving" '989 Patent, claim 1

• Context and Importance: This phrase defines the required relationship between the administration of maribavir and the specified anticonvulsants. Its interpretation will determine whether infringement occurs only when the drugs are deliberately prescribed together or in any instance of overlapping presence in the patient's system.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The plain meaning of "exposed to" could be read broadly to cover any situation where both drugs are present in the patient, regardless of prescription instructions. The patent's general discussion of managing drug-drug interactions supports this view '989 Patent, col. 1:24-27
  • Evidence for a Narrower Interpretation: The context of providing a specific "treatment regimen" could support a narrower reading that requires the drugs to be administered together as part of a coordinated medical plan. The specification's focus on adjusting doses for known co-administered drugs may suggest an intentional, rather than coincidental, overlap '989 Patent, col. 5:1-12

VI. Other Allegations

• Indirect Infringement: The complaint alleges both induced and contributory infringement for all six patents-in-suit Compl. ¶37 Compl. ¶38 The basis for inducement is the allegation that Sun's product labeling will instruct and encourage infringing uses Compl. ¶13 The basis for contributory infringement is the allegation that Sun's product is especially adapted for an infringing use and has no substantial non-infringing use Compl. ¶38
• Willful Infringement: The complaint does not use the term "willful infringement" but alleges for each patent that the case is "an exceptional one" and requests an award of attorneys' fees under 35 U.S.C. § 285 Compl. ¶41 Compl. ¶50 Compl. ¶59 Compl. ¶68 Compl. ¶77 Compl. ¶86 The basis for knowledge is the allegation that Sun has been aware of each patent since at least the date of its ANDA submission, a common allegation in ANDA litigation stemming from the Orange Book listing of the patents Compl. ¶39 Compl. ¶48 Compl. ¶57 Compl. ¶66 Compl. ¶75 Compl. ¶84

VII. Analyst's Conclusion: Key Questions for the Case

• A central issue will be one of induced infringement: Will the language of Sun's proposed generic drug label be found to specifically instruct or encourage physicians and patients to administer maribavir in a manner that meets all limitations of the asserted method claims, such as adjusting doses for co-administered drugs or administering under specific food conditions?
• A key factual question for the composition patent will be one of chemical identity: Will discovery and testing reveal that Sun's ANDA product, as formulated for commercial production, contains the specific low levels of impurities claimed in the '940 patent, thereby falling within the scope of its composition claims?
• The litigation may also turn on a question of claim construction and scope: How will the court define the boundaries between mutually exclusive administration methods, such as "with food" versus "fasted condition," and will those definitions be broad enough to read on the instructions in Sun's proposed label?